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Background: To investigate antiviral potency of the 2-drug regimen
(2DR) dolutegravir plus lamivudine vs the 3-drug regimen (3DR)
dolutegravir plus tenofovir disoproxil fumarate/emtricitabine, we per-
formed a post-hoc analysis assessing antiviral response rates in the phase
III GEMINI-1 and GEMINI-2 studies by baseline viral load (VL).
Setting: One hundred ninety-two centers in 21 countries.
Methods: Treatment-naive HIV-1–infected participants with
screening VL #500,000 copies/mL were randomized 1:1 to once-
daily dolutegravir plus lamivudine or dolutegravir plus tenofovir
disoproxil fumarate/emtricitabine. Median change from baseline was
determined for log10-transformed VL in the overall study population
and the subpopulation with baseline VL .100,000 copies/mL.
Proportion of participants achieving plasma VL ,50 copies/mL
(Snapshot algorithm) or ,40 copies/mL (Abbott RealTime HIV-1
assay) and target not detected was assessed through week 48 by
baseline VL. Time to viral suppression was determined (nonpara-
metric Kaplan–Meier method).
Results: For 293 participants with baseline VL .100,000
copies/mL, median change from baseline at week 4 was 23.38
and 23.40 log10 copies/mL in the 2DR and 3DR groups, respec-
tively; reduction was sustained throughout 48 weeks. Time to VL
,50 copies/mL was longer in participants with baseline VL
.100,000 copies/mL than the overall study population (57 [week
8] vs 29 days [week 4]) and similar between the 2DR and 3DR
groups. Proportion of participants with VL ,50 or ,40 copies/mL
and target not detected was similar between groups, irrespective of
baseline VL, at all tested visits throughout 48 weeks.
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Conclusion: Dolutegravir plus lamivudine demonstrates high
antiviral potency in treatment-naive HIV-1–infected individuals
across baseline VL strata.
Key Words: HIV-1 infection, antiretroviral therapy, virologic
response, 2-drug regimen, treatment-naive, viral load
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INTRODUCTION
The introduction of combination antiretroviral therapy
(ART) has led to substantial increases in life expectancy
among people living with HIV (PLHIV).1 As mortality rates
among PLHIV decline and life expectancy approaches that of
the general population,1 concerns about adverse effects
associated with long-term ART use have prompted interest
in reducing the number of drugs in antiretroviral regimens
to minimize cumulative drug exposure.2
The phase III GEMINI-1 and GEMINI-2 studies
demonstrated noninferior virologic efficacy for the 2-drug
regimen (2DR) dolutegravir plus lamivudine compared with
the 3-drug regimen (3DR) dolutegravir plus tenofovir dis-
oproxil fumarate/emtricitabine fixed-dose combination at
week 48 for treatment-naive participants with screening
HIV-1 viral load (VL) #500,000 copies/mL.3 In these
studies, 716 and 717 participants received the 2DR and
3DR, respectively; only 6 and 4 participants met protocol-
defined virologic withdrawal criteria through week 48, and no
treatment-emergent resistance to integrase strand transfer
inhibitors or nucleoside reverse transcriptase inhibitors
(NRTIs) occurred.3
The efficacy of an antiretroviral regimen in patients
with high VL is an important indicator of regimen potency.4
Ritonavir-boosted darunavir plus raltegravir is a 2DR that
failed to demonstrate noninferiority to a standard-of-care 3DR
in participants with baseline VL .100,000 copies/mL despite
demonstrating noninferiority in the overall study population.5
To evaluate the potency of the 2DR dolutegravir plus
lamivudine, virologic response in participants by baseline
VL was analyzed post-hoc using pooled data from the
GEMINI studies.
METHODS
The GEMINI studies were identically designed, double-
blind, randomized, phase III trials conducted at 192 centers in
21 countries in participants aged $18 years with HIV-1
infection who were ART-naive. The GEMINI studies initially
included participants with screening VL 1000 to 100,000
copies/mL; however, as supported by the protocol, the upper
limit was increased to 500,000 copies/mL after an indepen-
dent review of data from other trials investigating dolute-
gravir plus lamivudine (methodology described previously).3
In some participants with screening VL#500,000 copies/mL,
VL exceeded .500,000 copies/mL at baseline. Those with
hepatitis B or pre-existing major mutations conferring
resistance to NRTIs, nonnucleoside reverse transcriptase
inhibitors, or protease inhibitors were excluded.
Written informed consent was obtained from each
participant before study entry, and study protocols were
approved by appropriate ethics committees and institutional
review boards in accordance with the Declaration of Helsinki
and the International Conference on Harmonization Guideline
for Good Clinical Practice.
Participants were randomized 1:1 to a once-daily oral
regimen of either dolutegravir (50 mg) plus lamivudine (300
mg) or dolutegravir (50 mg) plus tenofovir disoproxil
fumarate (300 mg)/emtricitabine (200 mg).
The primary endpoint of the GEMINI studies was
proportion of participants with plasma VL ,50 copies/mL at
week 48 according to the Snapshot algorithm in the intention-
to-treat–exposed (ITT-E) population. VL decline to ,50
copies/mL was evaluated as median change in log10-trans-
formed VL from baseline at weeks 4, 8, 12, 16, 24, 36, and
48, and time to viral suppression (plasma VL,50 copies/mL)
was determined using the nonparametric Kaplan–Meier
method. Proportion of participants with plasma VL ,50
copies/mL at weeks 4, 8, 12, 16, 24, 36, and 48 according to
the Snapshot algorithm were compared between the 2DR and
3DR groups by baseline VL. The Abbot RealTime HIV-1
assay used to measure VLs has a lower limit of detection of
40 copies/mL. Therefore, we conducted an exploratory
analysis where VLs from 40 to 10,000,000 copies/mL were
reported qualitatively as target detected or target not detected
(TND) for samples with VL ,40 copies/mL. In addition,
TND data were used to compare the proportion of participants
with undetectable VL summarized by visit and at week 48 by
baseline VL.
CD4+ cell count by baseline VL (.100,000 and
#100,000 copies/mL) was determined at week 48, and
change from baseline was estimated using an ANCOVA
model adjusting for study (GEMINI-1 vs GEMINI-2),
baseline plasma VL, baseline CD4+ cell count, subgroup,
and treatment by relevant subgroup interaction.
RESULTS
Participant Characteristics
As previously reported, baseline demographics were
similar between the 2DR and 3DR groups in the pooled
GEMINI-1 and GEMINI-2 ITT-E populations.3 Median age
(range) was 32 (18–72) years in the 2DR group and 33
(18–70) years in the 3DR group, and 16% (113/716) and 14%
(98/717) of participants in the 2DR and 3DR groups,
respectively, were women. Most participants were white
[2DR, 67% (480/716); 3DR, 69% (497/717)] and non-
Hispanic/Latino [2DR, 70% (501/716); 3DR, 68% (485/
717)].
Both groups were well-balanced regarding proportion
of participants in each VL and CD4+ cell count strata. A
majority of participants in each group had VL #100,000
copies/mL at baseline [2DR, 80% (n = 576); 3DR, 79% (n =
564)]. Twenty percent (n = 140) of participants in the 2DR
group and 21% (n = 153) in the 3DR group had baseline VL
.100,000 copies/mL; 7% (n = 51) and 6% (n = 46) had
.250,000 copies/mL; 3% (n = 18) and 3% (n = 24) had
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.400,000 copies/mL; and 2% (n = 13) and 2% (n = 15) had
.500,000 copies/mL (after screening VL #500,000
copies/mL). Median (range) CD4+ cell count was 427
(19–1399) cells/mm3 in the 2DR group and 438 (19–1497)
cells/mm3 in the 3DR group. In total, 9% (63/716) and 8%
(55/717) of participants in the 2DR and 3DR groups,
respectively, had #200 cells/mm3.
Virologic Response by Baseline VL
Median change in VL from baseline at week 4 was
22.77 and 22.80 log10 copies/mL in the overall population
of the 2DR and 3DR groups, respectively.3 In participants
with baseline VL .100,000 copies/mL, median change from
baseline at week 4 was 23.38 and 23.40 log10 copies/mL in
the 2DR and 3DR groups, respectively. In both the overall
population and in those with baseline VL .100,000
copies/mL, reduction in VL was maintained through 48
weeks. Viral suppression (VL ,50 copies/mL) was achieved
at a median of 29 days (week 4 visit) in both groups in the
overall study population [hazard ratio (HR), 1.01; 95%
confidence interval (CI): 0.91 to 1.12] and in those with
baseline VL#100,000 copies/mL (HR, 0.99; 95% CI: 0.88 to
1.11); for participants with baseline VL.100,000 copies/mL,
viral suppression was achieved at a median of 57 days (week
8 visit) in both groups (HR, 1.00; 95% CI: 0.79 to 1.26).
Overall, 72% (518/716) of participants in the 2DR
group and 70% (504/717) in the 3DR group achieved viral
suppression (VL ,50 copies/mL) at week 4. For participants
with baseline VL #100,000 copies/mL, based on the
Snapshot algorithm, 83% (477/576) in the 2DR group and
81% (456/564) in the 3DR group achieved viral suppression
by week 4 compared with 29% (41/140) and 31% (48/153) of
participants with baseline VL .100,000 copies/mL in the
2DR and 3DR groups, respectively (Fig. 1A). At week 24, the
proportion of participants with VL ,50 copies/mL was
similarly high in both groups, regardless of baseline VL,
and the response was sustained through week 48. Across all
baseline VL strata, high and similar rates of viral suppression
were observed in the Snapshot analysis at week 48 in both
groups, including in participants whose VL increased to
exceed 500,000 copies/mL between the screening and
baseline assessments (Fig. 1B).
Assessment of qualitative TND data showed 34% (246/
716) in the 2DR group and 32% (228/717) in the 3DR group
had undetectable VL at week 4, and 77% (553/716) in the
2DR group and 73% (525/717) in the 3DR group had
undetectable VL at week 48 (Fig. 2A). Among participants
with baseline VL .100,000 copies/mL, 64% (90/140) in the
2DR group and 52% (79/153) in the 3DR group had
undetectable VL at week 48 (unadjusted treatment difference,
12.7%; 95% CI: 1.4 to 23.9; Fig. 2B). Proportions of
participants with undetectable VL were similar between
treatment groups in the other baseline VL subgroups.
Change in CD4+ Cell Count by Baseline VL
For participants with baseline VL #100,000 copies/mL,
median (interquartile range) CD4+ cell count increased by 206
(109–303) cells/mm3 in the 2DR group and by 191 (101–304)
cells/mm3 in the 3DR group at week 48 [adjusted mean
difference (95% CI), 7.2 (214.6 to 29.0) cells/mm3]. For
participants with baseline VL .100,000 copies/mL, median
(interquartile range) CD4+ cell count increased by 233
(151–344) cells/mm3 in the 2DR group and by 211
(125–359) cells/mm3 in the 3DR group at week 48 [adjusted
mean difference (95% CI), 7.4 (235.9 to 50.8) cells/mm3].
DISCUSSION
In the GEMINI studies, the 2DR dolutegravir plus
lamivudine was associated with a rapid rate of decline in VL,
comparable to that achieved with the 3DR dolutegravir plus
tenofovir disoproxil fumarate/emtricitabine, with most partic-
ipants achieving virologic suppression within 4 weeks at the
,50 copies/mL level. In addition, proportion of participants
with undetectable VL and TND using the Abbott RealTime
assay was similar between groups over time through week 48
and also across VL strata at week 48. These data demonstrate
the potency of dolutegravir plus lamivudine in the treatment
of HIV-1 infection, similar to that of a standard-of-care 3DR.
An update to the US Department of Health and Human
Services (DHHS) treatment guidelines based on the GEMINI
results supports the use of dolutegravir plus lamivudine as
initial therapy for HIV-1 infection in PLHIV who have HIV-1
RNA #500,000 copies/mL, no active hepatitis B infection,
and available HIV genotype information.6 According to the
DHHS, demonstration of long-term efficacy of the 2DR
dolutegravir plus lamivudine supports the recommendation of
this regimen for use as initial therapy. A preplanned analysis
of the GEMINI studies showed that dolutegravir plus
lamivudine maintained noninferior efficacy compared with
dolutegravir plus tenofovir disoproxil fumarate/emtricitabine
at 96 weeks, with low rates of confirmed virologic withdrawal
and no treatment-emergent INSTI or NRTI mutations.7
A question regarding the adoption of 2DRs in favor of
the mainstay 3DRs is whether 2DRs can provide equivalent
efficacy.2 Treatment guidelines have considered VL
.100,000 copies/mL and CD4+ cell count ,200 cells/mm3
as limitations for the use of 2DRs,4 and a shift toward
widespread use of 2DRs will require demonstration that the
regimen is sufficiently potent to provide virologic suppression
in these populations. In a single-arm study of raltegravir plus
ritonavir-boosted darunavir, baseline VL .100,000
copies/mL (HR, 3.76; 95% CI: 1.52 to 9.31; P = 0.004)
and lower CD4+ cell count (HR, 0.77; 95% CI: 0.61 to 0.98
cells per 100 cells/mm3 increase; P = 0.037) were associated
with virologic failure,8 and in a randomized trial, raltegravir
plus ritonavir-boosted darunavir was noninferior to a 3DR of
raltegravir plus 2 NRTIs in the overall study population, but
inferior in participants with baseline VL.100,000 copies/mL
and CD4+ cell count ,200 cells/mm3.5 These trials included
participants with baseline VL .500,000 copies/mL, although
patient numbers in these subgroups were small, as in the
GEMINI studies. The data described here demonstrate that
dolutegravir plus lamivudine has similar efficacy to dolute-
gravir plus tenofovir disoproxil fumarate/emtricitabine in
participants with baseline VL .100,000 copies/mL, with no
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indication of declining activity in the higher VL strata. Not
unexpectedly, the time to achieve virologic suppression was
longer (and similar) in both groups for participants with
baseline VL .100,000 copies/mL, whereas both baseline VL
subgroups in both treatment groups were suppressed at
the week 24 time point. This difference across populations
is difficult to apply to a clinical decision regarding the
concept of U = U (undetectable virus = untransmittable virus),
which should be based on individual VL results and
clinical circumstances.
Previously it was shown that for the small subset of
participants with baseline CD4+ cell count #200 cells/mm3,
a lower proportion in the 2DR group achieved virologic
suppression compared with the 3DR group [79% (50/63) vs
FIGURE 1. Snapshot analysis of virologic response
(VL ,50 copies/mL) (A) by treatment week and
(B) at week 48 by baseline VL, in the ITT-E pop-
ulation. 2DR, 2-drug regimen (dolutegravir plus
lamivudine); 3DR, 3-drug regimen (dolutegravir
plus tenofovir disoproxil fumarate/emtricitabine).
aParticipants were required to have VL #500,000
copies/mL at screening; however, VL had
increased to exceed 500,000 copies/mL at base-
line in some participants.
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93% (51/55)].3 The reasons for failure for most of the
participants in this subgroup were unrelated to virologic
efficacy or treatment-related adverse events. In this subgroup,
only 5% (3/63) in the 2DR group and 2% (1/55) in the 3DR
group had VL $50 copies/mL at week 48. Only 1 participant
in the 2DR group and none in the 3DR group met confirmed
virologic withdrawal criteria.
The GEMINI studies had several limitations, as
described elsewhere.3 The study populations were predomi-
nantly composed of men under age 50 and are not fully
reflective of the global population of PLHIV. Furthermore,
the exclusion of participants with VL .500,000 copies/mL at
screening and the small numbers of participants with VL
.500,000 copies/mL at baseline preclude consideration of
the use of dolutegravir plus lamivudine in those with very
high VLs.
This post-hoc analysis of the GEMINI studies demon-
strates that a 2DR of dolutegravir plus lamivudine that
FIGURE 2. Proportion of participants with VL,40
copies/mL and TND (as assessed by Abbott Real-
Time HIV-1 assay) (A) by treatment week and (B)
at week 48 by baseline VL, in the ITT-E population.
2DR, 2-drug regimen (dolutegravir plus lam-
ivudine); 3DR, 3-drug regimen (dolutegravir plus
tenofovir disoproxil fumarate/emtricitabine).
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reduces cumulative drug exposure was as potent as a standard
3DR in suppressing viral replication in PLHIV with VL up to
500,000 copies/mL.
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